登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、桂林莱茵生物科技股份有限公司（以下简称"公司"）于2025年12月24日披露了《关于控股股东签署 〈控制权变更框架协议〉〈股份转让协议〉〈表决权放弃协议〉〈不谋求控制权承诺函〉及公司签署 〈发行股份购买资产协议〉〈附条件生效的股份认购协议〉〈股权转让协议〉暨控制权拟发生变更的提 示性公告》（公告编号：2025-076）、《桂林莱茵生物科技股份有限公司发行股份购买资产并募集配套 资金暨关联交易预案》（以下简称"《交易预案》"）及其摘要，在上述披露文件中对本次控制权变更、 发行股份购买资产并募集配套资金事项（以下统称"本次交易"）所涉及的有关风险因素及尚需履行的审 批程序进行了详细说明，敬请广大投资者注意投资风险。 2、自本次交易披露以来，公司及相关各方积极推进本次交易所涉及的股份协议转让，标的公司尽职调 查、审计和评估等各项工作。截至本公告披露之日，上述工作正按计划有序推进中。公司将在相关工作 全部完成后，再次召开董事会审议本次交易的相关事项，并依照 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2026-003 桂林莱茵生物科技股份有限公司 关于公司控制权变更、发行股份购买资产并募集配套资金 暨关联交易事项的进展公告 （一）公司控股股东发生变更的具体情况 2025年12月22日，公司原控股股东、实际控制人秦本军先生与广州德福营养 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、桂林莱茵生物科技股份有限公司（以下简称"公司"）于2025年12月24 日披露了《关于控股股东签署<控制权变更框架协议><股份转让协议><表决权放 弃协议><不谋求控制权承诺函>及公司签署<发行股份购买资产协议><附条件生 效的股份认购协议><股权转让协议>暨控制权拟发生变更的提示性公告》（公告 编号：2025-076）、《桂林莱茵生物科技股份有限公司发行股份购买资产并募集 配套资金暨关联交易预案》（以下简称"《交易预案》"）及其摘要，在上述披 露文件中对本次控制权变更、发行股份购买资产并募集配套资金事项（以下统称 "本次交易"）所涉及的有关风险因素及尚需履行的审批程序进行了 ...

Core Viewpoint - The article highlights a significant trend in the A-share market, where there has been a surge in control changes among listed companies, reflecting increased market activity and strategic repositioning by various stakeholders [2][12]. Group 1: Control Changes in Listed Companies - Since 2025, at least 150 listed companies have announced plans for control changes, averaging one company every two days [2][3]. - As of 2026, over 60 companies have reported progress on control changes, indicating a continuation of this trend [2]. - The majority of control changes are occurring in traditional industries such as chemicals, textiles, and consumer goods, with acquirers including individuals, state-owned enterprises, and investment firms [2][5]. Group 2: Industry Distribution of Control Changes - The distribution of control changes shows that traditional industries dominate, with 12.77% of changes in the oil and petrochemical sector, and significant activity in environmental services, construction, and light manufacturing [5][7]. - Other sectors like agriculture, textiles, and real estate also show notable percentages of control changes, indicating a broad impact across various industries [5][7]. Group 3: Market Capitalization of Companies Involved - A significant portion of companies undergoing control changes are small-cap firms, with 169 companies having a market capitalization below 10 billion yuan, accounting for nearly 80% of the total [8][9]. - Companies with a market cap below 5 billion yuan represent 47.44%, while those between 5 billion and 10 billion yuan make up 31.16% [9][10]. Group 4: Motivations Behind Control Changes - The motivations for these control changes include financial distress among original controlling shareholders, strategic shifts in traditional industries, and pressures from debt [12][14]. - The trend is also driven by the need for new capital and resources to enhance company governance and operational efficiency [11][12]. Group 5: Types of Acquirers - The acquirers in these control changes are primarily state-owned enterprises, industrial capital, and limited partnership firms, with state-owned entities frequently taking over to optimize industrial layouts and stabilize the market [14]. - Industrial capital is also a significant player, often seeking to enhance synergies and expand into new business areas [14].

Core Viewpoint - The company is undergoing a change in control and asset acquisition, aiming for vertical integration of its supply chain through the acquisition of 95.5% of Beijing Jinkangpu's shares [1][2]. Group 1: Control Change and Management - The company plans to resume trading on December 24, 2025, and will initiate a control change and a comprehensive transaction plan [2]. - The original controlling shareholder intends to transfer 8.09% of shares and relinquish voting rights for 25.5% of shares, with Guangzhou Defu Nutrition Investment Partnership becoming the new controlling shareholder [2]. - As of February 10, 2026, the share transfer agreement and asset audit are progressing as planned, with the company committing to disclose updates every 30 days [2]. Group 2: Project Advancement - The acquisition is aimed at downstream vertical integration, focusing on synergy in technology, market, and raw materials [3]. - Beijing Jinkangpu possesses advantages in formula development and customer networks, which may enhance the company's application solution capabilities and customer loyalty post-acquisition [3]. - The effectiveness of the integration and the pace of business expansion will be key areas for long-term observation [3]. Group 3: Strategic Development - The company will continue to focus on high-quality market targets around its core business of natural health ingredients, considering both horizontal and vertical integration opportunities [4]. - The resources from Defu Capital may facilitate the company's transformation from a raw material supplier to a platform enterprise, potentially leading to governance optimization and resource integration [4]. Group 4: Capacity Expansion - The company has completed global capacity layout, but the new factories have a short operational history, resulting in low current capacity utilization [5]. - Future capacity release will depend on sales growth of core products, expansion into new categories, and the rollout of synthetic biology technology products [5].

另外，莱茵生物经过二十余年的深耕积淀，所形成的综合优势及行业地位，相信也是德福资本综合考量 的关键因素。一是产业布局完善、体系健全，公司拥有充足的产能储备、领先的生产技术、完善的QA 及QC质量管控体系、规范的治理结构，以及覆盖全球的销售网络，企业发展底盘坚实牢靠；二是公司 具备系统的选品、拓品与产品孵化能力， 这种能力依托于公司完整的研发、开发、产业化全链条布局，能够实现产品从概念到落地的高效转化； 三是具备业务持续升级的内驱力与技术迭代能力，公司始终保持敏锐的技术前瞻意识，近年来主动布局 合成生物、配方应用等前沿领域，并成功实现了技术的迭代升级，同时紧跟行业发展趋势，积极开拓动 物饲料、宠物营养等多元应用场景，体现了公司较好的发展活力与成长潜力。此次德福资本选择与莱茵 生物合作，既是对公司业务发展的高度认可，也彰显了对公司未来前景的坚定信心。 答：首先在战略层面，德福资本与莱茵生物都高度看好天然健康成分这一细分赛道，且德福资本对莱茵 生物的发展战略予以高度认可。双方在战略层面高度契合、理念一致，这是此次合作达成的基础前提， 也是核心驱动力之一。 格隆汇2月11日丨莱茵生物(002166.SZ)在投资者关系 ...

另外，莱茵生物经过二十余年的深耕积淀，所形成的综合优势及行业地位，相信也是德福资本综合考量 的关键因素。一是产业布局完善、体系健全，公司拥有充足的产能储备、领先的生产技术、完善的QA 及QC质量管控体系、规范的治理结构，以及覆盖全球的销售网络，企业发展底盘坚实牢靠；二是公司 具备系统的选品、拓品与产品孵化能力， 这种能力依托于公司完整的研发、开发、产业化全链条布局，能够实现产品从概念到落地的高效转化； 三是具备业务持续升级的内驱力与技术迭代能力，公司始终保持敏锐的技术前瞻意识，近年来主动布局 合成生物、配方应用等前沿领域，并成功实现了技术的迭代升级，同时紧跟行业发展趋势，积极开拓动 物饲料、宠物营养等多元应用场景，体现了公司较好的发展活力与成长潜力。此次德福资本选择与莱茵 生物合作，既是对公司业务发展的高度认可，也彰显了对公司未来前景的坚定信心。 答：首先在战略层面，德福资本与莱茵生物都高度看好天然健康成分这一细分赛道，且德福资本对莱茵 生物的发展战略予以高度认可。双方在战略层面高度契合、理念一致，这是此次合作达成的基础前提， 也是核心驱动力之一。 格隆汇2月11日丨莱茵生物(002166.SZ)在投资者关系 ...

Group 1: Transaction Overview - The transaction with Defo Capital involves the transfer of 8.09% equity from the original controlling shareholder and the acquisition of 95.5% equity in Beijing Jinkangpu, aimed at vertical integration in the industry [3][4] - The acquisition is expected to enhance the company's capabilities in customer service, channel diversification, and resource integration, providing strong support for future development [2][3] Group 2: Strategic Alignment - Defo Capital's focus on the health sector aligns with the company's strategic direction, recognizing the potential in natural health components [4][5] - The company has over 20 years of industry experience, a robust production capacity, and a comprehensive quality control system, making it an attractive partner for Defo Capital [5][6] Group 3: Business Development Plans - The company plans to focus on two main directions for its synthetic biology business: developing proprietary products and providing industrialization services for external clients [6][7] - The RM2 product, a key natural sweetener, is expected to reshape the market, with plans for promotion through high-quality product and formulation services [7][8] Group 4: Capacity and Utilization - The company has established multiple extraction facilities, ensuring sufficient capacity, but current utilization rates are low due to new facilities not yet being operational [8][9] - Future capacity release will depend on sales growth of core products and the introduction of new synthetic biology products into the market [9][10] Group 5: Global Operations - The upgrade of the U.S. extraction facility aims to enhance supply chain security and meet global customer demands, focusing on producing raw materials advantageous in North America [9][10] - The company plans to optimize overseas capacity and improve product delivery efficiency to achieve significant operational improvements in the U.S. market [9]

Core Insights - The Chinese red date extract market is projected to reach 1.197 billion yuan in 2024, reflecting a year-on-year increase of 5.3% driven by health consumption upgrades, policy support, and technological innovation [1][13][14] Market Overview - The red date extract is derived from the fruit of red dates and is primarily used in pharmaceuticals, health products, beverages, and food additives. It is characterized by a brownish-yellow to brown powder with a sweet taste, containing alkaloids, sugars, organic acids, and vitamins, which provide health benefits such as nourishing the body, regulating endocrine functions, enhancing immunity, and improving blood circulation [3][4] Industry Chain - The red date extract industry chain consists of three segments: - Upstream: Focuses on red date cultivation, agricultural supply, and initial processing equipment manufacturing, with major production concentrated in regions like Xinjiang, Hebei, Shandong, Shaanxi, and Shanxi [7][8] - Midstream: Involves the procurement, processing, and extraction of red dates [8] - Downstream: Encompasses applications in food and beverages, dietary supplements, cosmetics, and pharmaceuticals, catering to consumer demands for natural and healthy products [8][10] Competitive Landscape - The red date extract industry is characterized by a "leading enterprises dominate, small and medium enterprises differentiate" structure. Leading companies leverage their R&D capabilities and full industry chain advantages to maintain market dominance, while smaller firms focus on niche markets and differentiated services [14][15] Development Trends - The application of red date extract is expected to deepen across various sectors: - In the food sector, there will be a shift towards developing functional foods tailored for specific demographics such as the elderly and athletes [17] - In cosmetics, the extract's antioxidant and moisturizing properties will see broader applications in skincare products [17] - In pharmaceuticals, the extract's medicinal value will be further explored for potential use in treatments for cardiovascular issues and immune enhancement [17] Sustainability and Green Production - The industry will increasingly emphasize sustainable development and green production practices, promoting eco-friendly cultivation methods and optimizing resource utilization during production to minimize environmental impact [18] International Market Expansion - Companies will accelerate their international market strategies, responding to growing demand for natural health products in regions like North America and Europe, while leveraging e-commerce to enhance global reach [19]

Core Viewpoint - The agricultural, animal husbandry, and fishery sector is experiencing a strong upward trend, with the only agricultural ETF (159275) showing a price increase of 1.53%, recovering key moving averages [1][9][10] Group 1: Market Performance - The agricultural ETF (159275) opened with fluctuations but quickly surged, recovering the 5-day, 10-day, and 20-day moving averages [1][9] - Key stocks in the sector, such as Huisheng Biological and Lain Biological, reached their daily limit, while others like Haili Biological and Jinhai Biological saw significant gains [10][12] Group 2: Industry Insights - The pig farming sector faces supply pressures, and policy guidance may accelerate capacity reduction [12][13] - The poultry farming sector is influenced by frequent outbreaks of avian influenza, creating uncertainty in breeding stock imports, which could benefit the white feather chicken industry in the medium to long term [12][13] - The animal health industry continues to show potential for growth, with new products being launched to drive revenue [12][13] Group 3: Valuation and Investment Opportunities - The current valuation of the agricultural sector is relatively low, with the agricultural ETF's underlying index showing a price-to-book ratio of 2.5, placing it at the 23.53 percentile over the past five years, indicating a favorable long-term investment opportunity [3][12] - Investors are encouraged to consider the agricultural ETF (159275) for exposure to leading companies in the pig farming sector and other segments of the agricultural value chain [13][12]

Group 1 - The A-share influenza vaccine sector is experiencing a strong performance, with companies such as Da'an Gene, Hualan Biological Engineering, and Zhijiang Biological reaching their daily limit up [1] - Yongshun Biological has seen an increase of over 10%, indicating positive market sentiment towards the sector [1] - Other companies in the sector, including Dongfang Biological, Biological Shares, Zhongsheng Pharmaceutical, Yiling Pharmaceutical, and Rhine Biological, are also witnessing gains [1]